Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18037723 | 1.00 | MAPT (0.52) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL18082365 | 0.94 | MAPT (0.53) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL16692031 | 0.93 | MEN1 (0.43) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL14616550 | 0.83 | MAPT (0.53) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL14616551 | 0.82 | LMNA (0.47) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL16692026 | 0.82 | MEN1 (0.45) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL15290549 | 0.82 | LMNA (0.46) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL14642673 | 0.80 | LMNA (0.44) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL17236156 | 0.80 | MAPT (0.50) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL16687019 | 0.80 | MAPT (0.50) | MAPTKMT2AMEN1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10508081-B2 | Intermediates and methods for synthesizing calicheamicin derivatives | PFIZER INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-10508081-B2 | Intermediates and methods for synthesizing calicheamicin derivatives | PFIZER INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-20180134656-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | PFIZER INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134656-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | PFIZER INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134656-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | PFIZER INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9902691-B2 | Intermediates and methods for synthesizing calicheamicin derivatives | PFIZER INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902691-B2 | Intermediates and methods for synthesizing calicheamicin derivatives | PFIZER INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902691-B2 | Intermediates and methods for synthesizing calicheamicin derivatives | PFIZER INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9872922-B2 | Anti-EFNA4 antibody-drug conjugates | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170072066-A1 | ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES | PFIZER, INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20160251389-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | PFIZER INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251389-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | PFIZER INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251389-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | PFIZER INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9381205-B2 | Anti-EFNA4 antibody-drug conjugates | PFIZER, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150125472-A1 | ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES | STEM CENTRX, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| WO-2015063680-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | PFIZER INC. (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10508081-B2 | Intermediates and methods for synthesizing calicheamicin derivatives | CALR, CALD1, CYCS | MAPT 4253/4885KMT2A 4788/4885MEN1 3898/4885 |
| US-20160251389-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | CALR, CALD1, CYCS | MAPT 4253/4885KMT2A 4788/4885MEN1 3898/4885 |
| US-20180134656-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | CALR, CALD1, CYCS | MAPT 4253/4885KMT2A 4788/4885MEN1 3898/4885 |
| US-20170072066-A1 | ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES | EFNA1, ACTN4, AFF4 | MAPT 2270/4885KMT2A 2007/4885MEN1 3636/4885 |
| US-20150125472-A1 | ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES | EFNA1, ACTN4, AFF4 | MAPT 2270/4885KMT2A 2007/4885MEN1 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.